OncoMed Pharmaceuticals Inc (OMED)

4.08
0.17 4.30
NASDAQ : Health Care
Prev Close 3.91
Open 3.89
Day Low/High 3.87 / 4.08
52 Wk Low/High 8.42 / 23.98
Volume 436.61K
Avg Volume 369.20K
Exchange NASDAQ
Shares Outstanding 37.62M
Market Cap 141.84M
EPS -3.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Closing Bell: Stocks End Higher As Corporate Earnings Take Focus

Closing Bell: Stocks End Higher As Corporate Earnings Take Focus

Stocks remained in positive territory breaking a three-day losing streak ahead of U.S. corporate earnings this week, despite mounting tension between North Korea and the U.S.

Stocks Higher Ahead of Earnings From Netflix, United Airlines

Stocks Higher Ahead of Earnings From Netflix, United Airlines

Stocks rise on Monday ahead of a big week for U.S. corporate earnings, including reports Monday from Netlfix and United Airlines.

Stocks Higher as Wall Street Focuses on Earnings and Mixed Economic Data

Stocks Higher as Wall Street Focuses on Earnings and Mixed Economic Data

Stocks rise on Monday ahead of a big week for U.S. corporate earnings and as the U.S. issues a warning to North Korea.

Biotech Movers: OncoMed, Incyte, Omeros

Biotech Movers: OncoMed, Incyte, Omeros

OncoMed Pharmaceuticals, Incyte and Omeros were among the biotech stock movers in premarket trading on Monday.

Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk

Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk

OncoMed Pharmaceuticals, Geron and Akorn were among the biotech stock movers in premarket trading on Monday.

Oversold Conditions For OncoMed Pharmaceuticals (OMED)

Oversold Conditions For OncoMed Pharmaceuticals (OMED)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

OncoMed Pharmaceuticals Announces Bayer Terminates Its Option To License Vantictumab Or Ipafricept

OncoMed Pharmaceuticals Announces Bayer Terminates Its Option To License Vantictumab Or Ipafricept

OncoMed Retains Worldwide Rights to Both Wnt Pathway Programs

OncoMed's Phase 2 Demcizumab Pancreatic Cancer Trial Misses Primary Endpoint

OncoMed's Phase 2 Demcizumab Pancreatic Cancer Trial Misses Primary Endpoint

OncoMed Management to Host Conference Call/Webcast at 8:30 a.m. ET/5:30 a.m. PT to Review Top-line Results

OncoMed Highlights New Data Presented At The American Association For Cancer Research Annual Meeting 2017

OncoMed Highlights New Data Presented At The American Association For Cancer Research Annual Meeting 2017

Translational Research for Tarextumab, Rosmantuzumab and GITRL-Fc Trimer to Inform Clinical Programs

OncoMed Presents Preclinical Data For Anti-TIGIT Program At The American Association For Cancer Research Annual Meeting 2017

OncoMed Presents Preclinical Data For Anti-TIGIT Program At The American Association For Cancer Research Annual Meeting 2017

Anti-TIGIT Demonstrates Potent Anti-Tumor Activity in Preclinical Models

OncoMed Pharmaceuticals Stock Sees Short Interest Expand By 56.5%

OncoMed Pharmaceuticals Stock Sees Short Interest Expand By 56.5%

The most recent short interest data has been released for the 03/15/2017 settlement date, which shows a 1,022,767 share increase in total short interest for OncoMed Pharmaceuticals Inc. , to 2,831,493, an increase of 56.55% since 02/28/2017.

OncoMed Announces Multiple Abstracts Related To Anti-TIGIT Program Accepted For Presentation At The American Association For Cancer Research Annual Meeting 2017

OncoMed Announces Multiple Abstracts Related To Anti-TIGIT Program Accepted For Presentation At The American Association For Cancer Research Annual Meeting 2017

Additional Presentations will Highlight New Biomarker and Xenograft Data for Clinical Programs

Noteworthy Wednesday Option Activity: OMED, ZEN, FMI

Noteworthy Wednesday Option Activity: OMED, ZEN, FMI

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in OncoMed Pharmaceuticals Inc. , where a total of 1,100 contracts have traded so far, representing approximately 110,000 underlying shares.

5 Stocks Under $10 That Could Rocket Higher Soon

5 Stocks Under $10 That Could Rocket Higher Soon

Keep an eye on these cheap stocks.

These 5 Stocks Under $10 Could Get Hot Soon

These 5 Stocks Under $10 Could Get Hot Soon

Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.

Noteworthy Monday Option Activity: OMED, NKTR, MNKD

Noteworthy Monday Option Activity: OMED, NKTR, MNKD

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in OncoMed Pharmaceuticals Inc. , where a total volume of 978 contracts has been traded thus far today, a contract volume which is representative of approximately 97,800 underlying shares (given that every 1 contract represents 100 underlying shares).

RSI Alert: OncoMed Pharmaceuticals (OMED) Now Oversold

RSI Alert: OncoMed Pharmaceuticals (OMED) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.